Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Hydrocortisone (Primary) ; Ketoconazole (Primary) ; Lenalidomide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 16 Mar 2017 Planned End Date changed from 1 Dec 2016 to 20 Mar 2018.
- 16 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016.